Drugs / Triamcinalone Acetonide
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03920007 Background | Sep 2019 → May 2023 overdue | Leber congenital amaurosis 1 | Atsena Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03379168 Comparator | Apr 2018 → Apr 2023 | osteoarthritis, knee | Dustin L. Richter, MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triamcinalone Acetonide | “Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain...” NCT03379168 ↗ |
| Route | Other | “Route of administration: Peri-ocular injection” NCT03920007 ↗ |